With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Advancing Health in Africa

2.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma

3.

Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.

4.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

5.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot